7539 related articles for article (PubMed ID: 2521335)
21. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
[TBL] [Abstract][Full Text] [Related]
22. Identification of retinamides that are more potent than N-(4-hydroxyphenyl)retinamide in inhibiting growth and inducing apoptosis of human head and neck and lung cancer cells.
Sun SY; Yue P; Kelloff GJ; Steele VE; Lippman SM; Hong WK; Lotan R
Cancer Epidemiol Biomarkers Prev; 2001 Jun; 10(6):595-601. PubMed ID: 11401908
[TBL] [Abstract][Full Text] [Related]
23. Lack of correlation between plasmatic levels of retinol and RBP and thyroid hormones in breast cancer patients treated with the synthetic retinoid fenretinide.
Pizzichetta M; Formelli F; Bombardieri E; Bruni GF; Costa A
Int J Biol Markers; 1990; 5(4):208. PubMed ID: 2151235
[No Abstract] [Full Text] [Related]
24. Pharmacokinetics and pharmacodynamics of 9-cis-retinoic acid in healthy men.
Weber C; Dumont E
J Clin Pharmacol; 1997 Jul; 37(7):566-74. PubMed ID: 9243349
[TBL] [Abstract][Full Text] [Related]
25. Plasma kinetics of oral retinol in cancer patients.
Goodman GE; Alberts DS; Peng YM; Beaudry J; Leigh SA; Moon TE
Cancer Treat Rep; 1984 Sep; 68(9):1125-33. PubMed ID: 6478452
[TBL] [Abstract][Full Text] [Related]
26. Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl beta-glucuronide.
Formelli F; Barua AB; Olson JA
FASEB J; 1996 Jul; 10(9):1014-24. PubMed ID: 8801162
[TBL] [Abstract][Full Text] [Related]
27. Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells.
Oridate N; Suzuki S; Higuchi M; Mitchell MF; Hong WK; Lotan R
J Natl Cancer Inst; 1997 Aug; 89(16):1191-8. PubMed ID: 9274913
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of 4-(N-hydroxyphenyl)retinamide conjugated with poly(L-glutamic acid) against ovarian cancer xenografts.
Zou C; Brewer M; Cao X; Zang R; Lin J; Deng Y; Li C
Gynecol Oncol; 2007 Dec; 107(3):441-9. PubMed ID: 17854871
[TBL] [Abstract][Full Text] [Related]
29. Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide.
Sabichi AL; Hendricks DT; Bober MA; Birrer MJ
J Natl Cancer Inst; 1998 Apr; 90(8):597-605. PubMed ID: 9554442
[TBL] [Abstract][Full Text] [Related]
30. Plasma vitamin A, retinol-binding protein, and prealbumin in postoperative breast cancer patients.
Basu TK; Sasmal P
Int J Vitam Nutr Res; 1988; 58(3):281-3. PubMed ID: 3198314
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of N-(4-hydroxyphenyl)-all-trans-retinamide in rats.
Swanson BN; Zaharevitz DW; Sporn MB
Drug Metab Dispos; 1980; 8(3):168-72. PubMed ID: 6104581
[TBL] [Abstract][Full Text] [Related]
32. Retinol-binding protein secretion from the liver of N-(4-hydroxyphenyl) retinamide-treated rats.
Ritter SJ; Smith JE
Biochim Biophys Acta; 1996 Jun; 1290(2):157-64. PubMed ID: 8645719
[TBL] [Abstract][Full Text] [Related]
33. Secretion of N-(4-hydroxyphenyl) retinamide-retinol-binding protein from liver parenchymal cells: evidence for reduced affinity of the complex for transthyretin.
Holven KB; Natarajan V; Gundersen TE; Moskaug JO; Norum KR; Blomhoff R
Int J Cancer; 1997 May; 71(4):654-9. PubMed ID: 9178822
[TBL] [Abstract][Full Text] [Related]
34. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients.
Rotmensz N; De Palo G; Formelli F; Costa A; Marubini E; Campa T; Crippa A; Danesini GM; Delle Grottaglie M; Di Mauro MG
Eur J Cancer; 1991; 27(9):1127-31. PubMed ID: 1835622
[TBL] [Abstract][Full Text] [Related]
35. Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer.
Clifford JL; Sabichi AL; Zou C; Yang X; Steele VE; Kelloff GJ; Lotan R; Lippman SM
Cancer Epidemiol Biomarkers Prev; 2001 Apr; 10(4):391-5. PubMed ID: 11319181
[TBL] [Abstract][Full Text] [Related]
36. Vaginal hydrolysis of retinyl acetate: increase in plasma retinol and retinol binding protein in women with cervical dysplasias.
Palan PR; Basu J; Romney SL
Biochem Med Metab Biol; 1988 Dec; 40(3):282-90. PubMed ID: 3233185
[TBL] [Abstract][Full Text] [Related]
37. Pharmacology of 13-cis-retinoic acid in humans.
Kerr IG; Lippman ME; Jenkins J; Myers CE
Cancer Res; 1982 May; 42(5):2069-73. PubMed ID: 7039821
[TBL] [Abstract][Full Text] [Related]
38. The pharmacokinetics of all-trans-retinoic acid and N-(2-hydroxyethyl)retinamide in mice as determined with a sensitive and convenient procedure. Solid-phase extraction and reverse-phase high performance liquid chromatography.
McPhillips DM; Kalin JR; Hill DL
Drug Metab Dispos; 1987; 15(2):207-11. PubMed ID: 2882980
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma.
Modiano MR; Dalton WS; Lippman SM; Joffe L; Booth AR; Meyskens FL
Invest New Drugs; 1990 Aug; 8(3):317-9. PubMed ID: 2148744
[TBL] [Abstract][Full Text] [Related]
40. Plasma retinol and retinol binding protein concentrations in patients on maintenance haemodialysis with and without vitamin A supplements.
Stewart WK; Fleming LW
Nephron; 1982; 30(1):15-21. PubMed ID: 7201081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
